Skip to content

NNRTIs and protease inhibitors both good for first ART, channelling affects choices

Infants in southern Africa start antiretroviral therapy late with advanced disease

No to treating our way out of the epidemic, say South African experts

Sofosbuvir/ledipasvir safe and effective for genotype 1 HCV

Inflammatory markers associated with development of diabetes in people taking HIV therapy

High effectiveness seen in English PrEP trial

Targeted adherence measures and viral load monitoring needed to improve retention in South African ART programme

HIV stigma starts young, but can be corrected, African schoolchildren's study shows

Care programme improves clinic attendance and rates of virologic suppression among vulnerable HIV-positive patients in New York